CHICAGO--(BUSINESS WIRE)--Sherman Biotech Inc., a wholly-owned subsidiary of Early Detect, Inc., announced today that it has scheduled seminars this fall in Chicago, Boston and New York City to discuss the company’s plans to begin preclinical studies and clinical trials of SB15, a newly-formulated compound for the treatment of anxiety associated with fragile X syndrome and autism. SB15 shows promise as an alternative to current drug therapies, such as stimulants, antidepressants and anticonvulsants that broadly suppress anxiety in individuals with these conditions. “Our research shows that the formulated version of SB15 could have therapeutic benefits for anxiety in appropriate patients,” said Dr. David Schwartz, Sherman Biotech’s chief science officer.
